sigallab.net Open in urlscan Pro
50.62.198.70  Public Scan

Form analysis
0 forms found in the DOM

Text Content

SIGALLAB

CV Alex Sigal


LAB INTERESTS

1) IMMUNE ESCAPE AND CHANGES IN PATHOGENICITY OF SARS-COV-2 VARIANTS: WE WERE
THE FIRST TO CHARACTERIZE THE IMMUNE ESCAPE OF OMICRON.

2) PATHOGEN EVOLUTION DURING LONG-TERM INFECTION IN IMMUNOSUPPRESSION

3) CELL-TO-CELL SPREAD STRATEGIES THAT PATHOGENS USE TO OVERCOME IMMUNITY


LAB PI AND MEMBERS

Alex Sigal is faculty at the Africa Health Research Institute and Associate
Professor at the University of KwaZulu-Natal. Alex has a PhD in Systems Biology
from the Weizmann Institute and was a postdoctoral fellow with David Baltimore
at the California Institute of Technology. Sandile Cele, Farina Karim, and
Khadija Khan, all from KwaZulu-Natal, South Africa, are PhD students in the lab
and lead many of the projects. Lab staff are Yashica Ganga (Lab supervisor),
Zesuliwe Jule (Technologist), Kajal Reedoy (Technologist), and Mallory Bernstein
(Data Specialist).


PREPRINTS

SARS-COV-2 EVOLVES INCREASED INFECTION ELICITED CELL DEATH AND FUSION IN AN
IMMUNOSUPPRESSED INDIVIDUAL. MANUSCRIPT.

BETA INFECTION COMBINED WITH PFIZER BNT162B2 VACCINATION LEADS TO BROADENED
NEUTRALIZING IMMUNITY AGAINST OMICRON. MANUSCRIPT.


PUBLICATIONS


2022

CELE, S., JACKSON, L., KHOURY, D. S., KHAN, K., MOYO-GWETE, T., TEGALLY, H.,
SAN, J. E., CROMER, D., SCHEEPERS, C., AMOAKO, D. G., KARIM, F., BERNSTEIN, M.,
LUSTIG, G., ARCHARY, D., SMITH, M., GANGA, Y., JULE, Z., REEDOY, K., HWA, S. H.,
GIANDHARI, J., BLACKBURN, J. M., GOSNELL, B. I., ABDOOL KARIM, S. S., HANEKOM,
W., VON GOTTBERG, A., BHIMAN, J. N., LESSELLS, R. J., MOOSA, M. S., DAVENPORT,
M. P., DE OLIVEIRA, T., MOORE, P. L. & SIGAL, A. OMICRON EXTENSIVELY BUT
INCOMPLETELY ESCAPES PFIZER BNT162B2 NEUTRALIZATION. NATURE.

CELE, S., KARIM, F., LUSTIG, G., SAN, J. E., HERMANUS, T., TEGALLY, H., SNYMAN,
J., MOYO-GWETE, T., WILKINSON, E., BERNSTEIN, M., KHAN, K., HWA, S. H., TILLES,
S. W., SINGH, L., GIANDHARI, J., MTHABELA, N., MAZIBUKO, M., GANGA, Y., GOSNELL,
B. I., KARIM, S. S. A., HANEKOM, W., VAN VOORHIS, W. C., NDUNG’U, T., LESSELLS,
R. J., MOORE, P. L., MOOSA, M. S., DE OLIVEIRA, T. & SIGAL, A. SARS-COV-2
PROLONGED INFECTION DURING ADVANCED HIV DISEASE EVOLVES EXTENSIVE IMMUNE ESCAPE.
CELL HOST & MICROBE.

KHAN, K., KARIM, F., CELE, S., REEDOY, K., SAN, J. E., LUSTIG, G., TEGALLY, H.,
ROSENBERG, Y., BERNSTEIN, M., JULE, Z., GANGA, Y., NGCOBO, N., MAZIBUKO, M.,
MTHABELA, N., MHLANE, Z., MBATHA, N., MIYA, Y., GIANDHARI, J., RAMPHAL, Y.,
NAIDOO, T., SIVRO, A., SAMSUNDER, N., KHARSANY, A. B. M., AMOAKO, D., BHIMAN, J.
N., MANICKCHUND, N., KARIM, Q. A., MAGULA, N., ABDOOL KARIM, S. S., GRAY, G.,
HANEKOM, W., VON GOTTBERG, A., MILO, R., GOSNELL, B. I., LESSELLS, R. J., MOORE,
P. L., DE OLVEIRA, T., MOOSA, M. S. & SIGAL, A. OMICRON INFECTION ENHANCES DELTA
ANTIBODY IMMUNITY IN VACCINATED PERSONS. NATURE.

SIGAL, A., MILO, R. & JASSAT, W. ESTIMATING DISEASE SEVERITY OF OMICRON AND
DELTA SARS-COV-2 INFECTIONS NATURE REVIEWS IMMUNOLOGY.

SIGAL, A. MILDER DISEASE WITH OMICRON: IS IT THE VIRUS OR THE PRE-EXISTING
IMMUNITY? NATURE REVIEWS IMMUNOLOGY.

KHAN, K., KARIM, F., GANGA, Y., BERNSTEIN, M., JULE, Z., REEDOY, K., CELE, S.,
LUSTIG, G., AMOAKO, D., WOLTER, N., SAMSUNDER, N., SIVRO, A., SAN, J. E.,
GIANDHARI, J., TEGALLY, H., PILLAY, S., NAIDOO, Y., MAZIBUKO, M., MIYA, Y.,
NGCOBO, N., MANICKCHUND, N., MAGULA, N., KARIM, Q. A., VON GOTTBERG, A., ABDOOL
KARIM, S. S., HANEKOM, W., GOSNELL, B. I., LESSELLS, R. J., DE OLIVEIRA, T.,
MOOSA, M. S. & SIGAL, A. OMICRON BA.4/BA.5 ESCAPE NEUTRALIZING IMMUNITY ELICITED
BY BA.1 INFECTION. NATURE COMMUNICATIONS.

WELLS, G., GLASGOW, J. N., NARGAN, K., LUMAMBA, K., MADANSEIN, R., MAHARAJ, K.,
PERUMAL, L. Y., MATTHEW, M., HUNTER, R. L., PACL, H., PEABODY LEVER, J. E.,
STANFORD, D. D., SINGH, S. P., BAJPAI, P., MANNE, U., BENSON, P. V., ROWE, S.
M., LE ROUX, S., SIGAL, A., TSHIBALANGANDA, M., WELLS, C., DU PLESSIS, A.,
MSIMANG, M., NAIDOO, T. & STEYN, A. J. C. A HIGH-RESOLUTION 3D ATLAS OF THE
SPECTRUM OF TUBERCULOUS AND COVID-19 LUNG LESIONS. EMBO MOL MED.

KRAUSE, R., SNYMAN, J., SHI-HSIA, H., MUEMA, D., KARIM, F., GANGA, Y., NGOEPE,
A., ZUNGU, Y., GAZY, I., BERNSTEIN, M., KHAN, K., MAZIBUKO, M., MTHABELA, N.,
RAMJIT, D., LIMBO, O., JARDINE, J., SOK, D., WILSON, I. A., HANEKOM, W., SIGAL,
A., KLØVERPRIS, H., NDUNG’U, T. & LESLIE, A. HIV SKEWS THE SARS-COV-2 B CELL
RESPONSE TOWARD AN EXTRAFOLLICULAR MATURATION PATHWAY. ELIFE.

GREANEY, A. J., EGUIA, R. T., STARR, T. N., KHAN, K., FRANKO, N., LOGUE, J. K.,
LORD, S. M., SPEAKE, C., CHU, H. Y., SIGAL, A. & BLOOM, J. D. THE SARS-COV-2
DELTA VARIANT INDUCES AN ANTIBODY RESPONSE LARGELY FOCUSED ON CLASS 1 AND 2
ANTIBODY EPITOPES. PLOS PATHOGENS.

HWA, S. H., SNYMAN, J., BERNSTEIN, M., GANGA, Y., CELE, S., MUEMA, D., TAN, C.
W., KHAN, K., KARIM, F., HANEKOM, W., BERNSTEIN, L., KAUFMANN, S. H. E., WANG,
L. F., NDUNG’U, T. & SIGAL, A. HIV VIREMIA IS ASSOCIATED WITH COMPROMISED
SARS-COV-2 BETA VARIANT NEUTRALIZATION. J INFECT. DIS.

NKOSI, T., CHASARA, C., PAPADOPOULOS, A. O., NGUNI, T. L., KARIM, F., MOOSA, M.
S., GAZY, I., JAMBO, K., HANEKOM, W., SIGAL, A. & NDHLOVU, Z. M. UNSUPPRESSED
HIV INFECTION IMPAIRS T CELL RESPONSES TO SARS-COV-2 INFECTION AND ABROGATES T
CELL CROSS-RECOGNITION. ELIFE.

KEETON, R., TINCHO, M. B., NGOMTI, A., BAGUMA, R., BENEDE, N., SUZUKI, A., KHAN,
K., CELE, S., BERNSTEIN, M., KARIM, F., MADZORERA, S. V., MOYO-GWETE, T.,
MENNEN, M., SKELEM, S., ADRIAANSE, M., MUTITHU, D., AREMU, O., STEK, C., DU
BRUYN, E., VAN DER MESCHT, M. A., DE BEER, Z., DE VILLIERS, T. R., BODENSTEIN,
A., VAN DEN BERG, G., MENDES, A., STRYDOM, A., VENTER, M., GIANDHARI, J.,
NAIDOO, Y., PILLAY, S., TEGALLY, H., GRIFONI, A., WEISKOPF, D., SETTE, A.,
WILKINSON, R. J., DE OLIVEIRA, T., BEKKER, L. G., GRAY, G., UECKERMANN, V.,
ROSSOUW, T., BOSWELL, M. T., BHIMAN, J. N., MOORE, P. L., SIGAL, A., NTUSI, N.
A. B., BURGERS, W. A. & RIOU, C. T CELL RESPONSES TO SARS-COV-2 SPIKE
CROSS-RECOGNIZE OMICRON. NATURE.

MENG, B., ABDULLAHI, A., FERREIRA, I., GOONAWARDANE, N., SAITO, A., KIMURA, I.,
YAMASOBA, D., GERBER, P. P., FATIHI, S., RATHORE, S., ZEPEDA, S. K., PAPA, G.,
KEMP, S. A., IKEDA, T., TOYODA, M., TAN, T. S., KURAMOCHI, J., MITSUNAGA, S.,
UENO, T., SHIRAKAWA, K., TAKAORI-KONDO, A., BREVINI, T., MALLERY, D. L.,
CHARLES, O. J., BOWEN, J. E., JOSHI, A., WALLS, A. C., JACKSON, L., MARTIN, D.,
SMITH, K. G. C., BRADLEY, J., BRIGGS, J. A. G., CHOI, J., MADISSOON, E., MEYER,
K. B., MLCOCHOVA, P., CERON-GUTIERREZ, L., DOFFINGER, R., TEICHMANN, S. A.,
FISHER, A. J., PIZZUTO, M. S., DE MARCO, A., CORTI, D., HOSMILLO, M., LEE, J.
H., JAMES, L. C., THUKRAL, L., VEESLER, D., SIGAL, A., SAMPAZIOTIS, F.,
GOODFELLOW, I. G., MATHESON, N. J., SATO, K. & GUPTA, R. K. ALTERED TMPRSS2
USAGE BY SARS-COV-2 OMICRON IMPACTS INFECTIVITY AND FUSOGENICITY. NATURE.

REUSCHL, A. K., MESNER, D., SHIVKUMAR, M., WHELAN, M. V. X., PALLETT, L. J.,
GUERRA-ASSUNÇÃO, J. A., MADANSEIN, R., DULLABH, K. J., SIGAL, A., THORNHILL, J.
P., HERRERA, C., FIDLER, S., NOURSADEGHI, M., MAINI, M. K. & JOLLY, C. HIV-1 VPR
DRIVES A TISSUE RESIDENCY-LIKE PHENOTYPE DURING SELECTIVE INFECTION OF RESTING
MEMORY T CELLS. HIV-1 VPR DRIVES A TISSUE RESIDENCY-LIKE PHENOTYPE DURING
SELECTIVE INFECTION OF RESTING MEMORY T CELLS. CELL REPORTS.

GREANEY, A. J., STARR, T. N., EGUIA, R. T., LOES, A. N., KHAN, K., KARIM, F.,
CELE, S., BOWEN, J. E., LOGUE, J. K., CORTI, D., VEESLER, D., CHU, H. Y., SIGAL,
A. & BLOOM, J. D. A SARS-COV-2 VARIANT ELICITS AN ANTIBODY RESPONSE WITH A
SHIFTED IMMUNODOMINANCE HIERARCHY. PLOS PATHOGENS.

MARTIN, D. P., LYTRAS, S., LUCACI, A. G., MAIER, W., GRÜNING, B., SHANK, S. D.,
WEAVER, S., MACLEAN, O. A., ORTON, R. J., LEMEY, P., BONI, M. F., TEGALLY, H.,
HARKINS, G. W., SCHEEPERS, C., BHIMAN, J. N., EVERATT, J., AMOAKO, D. G., SAN,
J. E., GIANDHARI, J., SIGAL, A., WILLIAMSON, C., HSIAO, N. Y., VON GOTTBERG, A.,
DE KLERK, A., SHAFER, R. W., ROBERTSON, D. L., WILKINSON, R. J., SEWELL, B. T.,
LESSELLS, R., NEKRUTENKO, A., GREANEY, A. J., STARR, T. N., BLOOM, J. D.,
MURRELL, B., WILKINSON, E., GUPTA, R. K., DE OLIVEIRA, T. & KOSAKOVSKY POND, S.
L. SELECTION ANALYSIS IDENTIFIES CLUSTERS OF UNUSUAL MUTATIONAL CHANGES IN
OMICRON LINEAGE BA.1 THAT LIKELY IMPACT SPIKE FUNCTION. MOLECULAR BIOLOGY AND
EVOLUTION.

SCHEEPERS, C., EVERATT, J., AMOAKO, D. G., TEGALLY, H., WIBMER, C. K., MNGUNI,
A., ISMAIL, A., MAHLANGU, B., LAMBSON, B. E., MARTIN, D. P., WILKINSON, E., SAN,
J. E., GIANDHARI, J., MANAMELA, N., NTULI, N., KGAGUDI, P., CELE, S.,
RICHARDSON, S. I., PILLAY, S., MOHALE, T., RAMPHAL, U., NAIDOO, Y., KHUMALO, Z.
T., KWATRA, G., GRAY, G., BEKKER, L. G., MADHI, S. A., BAILLIE, V., VAN VOORHIS,
W. C., TREURNICHT, F. K., VENTER, M., MLISANA, K., WOLTER, N., SIGAL, A.,
WILLIAMSON, C., HSIAO, N. Y., MSOMI, N., MAPONGA, T., PREISER, W., MAKATINI, Z.,
LESSELLS, R., MOORE, P. L., DE OLIVEIRA, T., VON GOTTBERG, A. & BHIMAN, J. N.
EMERGENCE AND PHENOTYPIC CHARACTERIZATION OF THE GLOBAL SARS-COV-2 C.1.2
LINEAGE. NATURE COMMUNICATIONS.

TAN, C. W., CHIA, W. N., ZHU, F., YOUNG, B. E., CHANTASRISAWAD, N., HWA, S. H.,
YEOH, A. Y., LIM, B. L., YAP, W. C., PADA, S., TAN, S. Y., JANTARABENJAKUL, W.,
TOH, L. K., CHEN, S., ZHANG, J., MAH, Y. Y., CHEN, V. C., CHEN, M. I.,
WACHARAPLUESADEE, S., SIGAL, A., PUTCHAROEN, O., LYE, D. C. & WANG, L. F.
SARS-COV-2 OMICRON VARIANT EMERGED UNDER IMMUNE SELECTION. NAT MICROBIOL.


2021

CELE, S., GAZY, I., JACKSON, L., HWA, S. H., TEGALLY, H., LUSTIG, G., GIANDHARI,
J., PILLAY, S., WILKINSON, E., NAIDOO, Y., KARIM, F., GANGA, Y., KHAN, K.,
BERNSTEIN, M., BALAZS, A. B., GOSNELL, B. I., HANEKOM, W., MOOSA, M. S., NETWORK
FOR GENOMIC SURVEILLANCE IN SOUTH, A., TEAM, C.-K., LESSELLS, R. J., DE
OLIVEIRA, T. & SIGAL, A. ESCAPE OF SARS-COV-2 501Y.V2 FROM NEUTRALIZATION BY
CONVALESCENT PLASMA. NATURE.

KHAN, K., LUSTIG, G., BERNSTEIN, M., ARCHARY, D., CELE, S., KARIM, F., SMITH,
M., GANGA, Y., JULE, Z., REEDOY, K., MIYA, Y., MTHABELA, N., MAGULA, N. P.,
LESSELLS, R., DE OLIVEIRA, T., GOSNELL, B. I., KARIM, S. A., GARRETT, N.,
HANEKOM, W., GAIL-BEKKER, L., GRAY, G., BLACKBURN, J. M., MOOSA, M. S. & SIGAL,
A. IMMUNOGENICITY OF SARS-COV-2 INFECTION AND AD26.COV2.S VACCINATION IN PEOPLE
LIVING WITH HIV. CLIN. INFECT. DIS.

KARIM, F., GAZY, I., CELE, S., ZUNGU, Y., KRAUSE, R., BERNSTEIN, M., KHAN, K.,
GANGA, Y., RODEL, H., MTHABELA, N., MAZIBUKO, M., MUEMA, D., RAMJIT, D.,
NDUNG’U, T., HANEKOM, W., GOSNELL, B., LESSELLS, R. J., WONG, E. B., DE
OLIVEIRA, T., MOOSA, M. S., LUSTIG, G., LESLIE, A., KLØVERPRIS, H. & SIGAL, A.
HIV STATUS ALTERS DISEASE SEVERITY AND IMMUNE CELL RESPONSES IN BETA VARIANT
SARS-COV-2 INFECTION WAVE. ELIFE.

LUSTIG, G., CELE, S., KARIM, F., DERACHE, A., NGOEPE, A., KHAN, K., GOSNELL, B.
I., MOOSA, M. S., NTSHUBA, N., MARAIS, S., JEENA, P. M., GOVENDER, K., ADAMSON,
J., KLOVERPRIS, H., GUPTA, R. K., HARRICHANDPARSAD, R., PATEL, V. B. & SIGAL, A.
T CELL DERIVED HIV-1 IS PRESENT IN THE CSF IN THE FACE OF SUPPRESSIVE
ANTIRETROVIRAL THERAPY. PLOS PATHOGENS.

RODEL, H. E., FERREIRA, I., ZIEGLER, C. G. K., GANGA, Y., BERNSTEIN, M., HWA, S.
H., NARGAN, K., LUSTIG, G., KAPLAN, G., NOURSADEGHI, M., SHALEK, A. K., STEYN,
A. J. C. & SIGAL, A. AGGREGATED MYCOBACTERIUM TUBERCULOSIS ENHANCES THE
INFLAMMATORY RESPONSE. FRONTIERS.

SNYMAN, J., HWA, S. H., KRAUSE, R., MUEMA, D., REDDY, T., GANGA, Y., KARIM, F.,
LESLIE, A., SIGAL, A. & NDUNG’U, T. SIMILAR ANTIBODY RESPONSES AGAINST
SARS-COV-2 IN HIV UNINFECTED AND INFECTED INDIVIDUALS ON ANTIRETROVIRAL THERAPY
DURING THE FIRST SOUTH AFRICAN INFECTION WAVE. SIMILAR ANTIBODY RESPONSES
AGAINST SARS-COV-2 IN HIV UNINFECTED AND INFECTED INDIVIDUALS ON ANTIRETROVIRAL
THERAPY DURING THE FIRST SOUTH AFRICAN INFECTION WAVE. CLIN. INFECT. DIS.

TEGALLY, H., WILKINSON, E., LESSELLS, R. J., GIANDHARI, J., PILLAY, S., MSOMI,
N., MLISANA, K., BHIMAN, J. N., VON GOTTBERG, A., WALAZA, S., FONSECA, V.,
ALLAM, M., ISMAIL, A., GLASS, A. J., ENGELBRECHT, S., VAN ZYL, G., PREISER, W.,
WILLIAMSON, C., PETRUCCIONE, F., SIGAL, A., GAZY, I., HARDIE, D., HSIAO, N. Y.,
MARTIN, D., YORK, D., GOEDHALS, D., SAN, E. J., GIOVANETTI, M., LOURENCO, J.,
ALCANTARA, L. C. J. & DE OLIVEIRA, T. SIXTEEN NOVEL LINEAGES OF SARS-COV-2 IN
SOUTH AFRICA. NAT MED.

TEGALLY, H., WILKINSON, E., GIOVANETTI, M., IRANZADEH, A., FONSECA, V.,
GIANDHARI, J., DOOLABH, D., PILLAY, S., SAN, E. J., MSOMI, N., MLISANA, K., VON
GOTTBERG, A., WALAZA, S., ALLAM, M., ISMAIL, A., MOHALE, T., GLASS, A. J.,
ENGELBRECHT, S., VAN ZYL, G., PREISER, W., PETRUCCIONE, F., SIGAL, A., HARDIE,
D., MARAIS, G., HSIAO, N. Y., KORSMAN, S., DAVIES, M. A., TYERS, L., MUDAU, I.,
YORK, D., MASLO, C., GOEDHALS, D., ABRAHAMS, S., LAGUDA-AKINGBA, O.,
ALISOLTANI-DEHKORDI, A., GODZIK, A., WIBMER, C. K., SEWELL, B. T., LOURENÇO, J.,
ALCANTARA, L. C. J., KOSAKOVSKY POND, S. L., WEAVER, S., MARTIN, D., LESSELLS,
R. J., BHIMAN, J. N., WILLIAMSON, C. & DE OLIVEIRA, T. DETECTION OF A SARS-COV-2
VARIANT OF CONCERN IN SOUTH AFRICA. NATURE.

MADHI, S. A., BAILLIE, V., CUTLAND, C. L., VOYSEY, M., KOEN, A. L., FAIRLIE, L.,
PADAYACHEE, S. D., DHEDA, K., BARNABAS, S. L., BHORAT, Q. E., BRINER, C.,
KWATRA, G., AHMED, K., ALEY, P., BHIKHA, S., BHIMAN, J. N., BHORAT, A. E., DU
PLESSIS, J., ESMAIL, A., GROENEWALD, M., HORNE, E., HWA, S. H., JOSE, A., LAMBE,
T., LAUBSCHER, M., MALAHLEHA, M., MASENYA, M., MASILELA, M., MCKENZIE, S.,
MOLAPO, K., MOULTRIE, A., OELOFSE, S., PATEL, F., PILLAY, S., RHEAD, S., RODEL,
H., ROSSOUW, L., TAOUSHANIS, C., TEGALLY, H., THOMBRAYIL, A., VAN ECK, S.,
WIBMER, C. K., DURHAM, N. M., KELLY, E. J., VILLAFANA, T. L., GILBERT, S.,
POLLARD, A. J., DE OLIVEIRA, T., MOORE, P. L., SIGAL, A. & IZU, A. EFFICACY OF
THE CHADOX1 NCOV-19 COVID-19 VACCINE AGAINST THE B.1.351 VARIANT. EFFICACY OF
THE CHADOX1 NCOV-19 COVID-19 VACCINE AGAINST THE B.1.351 VARIANT. N ENGL J MED.

GARCIA-BELTRAN, W. F., LAM, E. C., ST DENIS, K., NITIDO, A. D., GARCIA, Z. H.,
HAUSER, B. M., FELDMAN, J., PAVLOVIC, M. N., GREGORY, D. J., POZNANSKY, M. C.,
SIGAL, A., SCHMIDT, A. G., IAFRATE, A. J., NARANBHAI, V. & BALAZS, A. B.
MULTIPLE SARS-COV-2 VARIANTS ESCAPE NEUTRALIZATION BY VACCINE-INDUCED HUMORAL
IMMUNITY. CELL.

SKELLY, D. T., HARDING, A. C., GILBERT-JARAMILLO, J., KNIGHT, M. L., LONGET, S.,
BROWN, A., ADELE, S., ADLAND, E., BROWN, H., MEDAWAR LABORATORY, T., TIPTON, T.,
STAFFORD, L., MENTZER, A. J., JOHNSON, S. A., AMINI, A., GROUP, O. C., TAN, T.
K., SCHIMANSKI, L., HUANG, K. A., RIJAL, P., GROUP, P. S., GROUP, C. M. P.-C.,
FRATER, J., GOULDER, P., CONLON, C. P., JEFFERY, K., DOLD, C., POLLARD, A. J.,
SIGAL, A., DE OLIVEIRA, T., TOWNSEND, A. R., KLENERMAN, P., DUNACHIE, S. J.,
BARNES, E., CARROLL, M. W. & JAMES, W. S. TWO DOSES OF SARS-COV-2 VACCINATION
INDUCE ROBUST IMMUNE RESPONSES TO EMERGING SARS-COV-2 VARIANTS OF CONCERN.
NATURE COMMUNICATIONS.

KOLLOLI, A., KUMAR, R., SINGH, P., NARANG, A., KAPLAN, G., SIGAL, A. & SUBBIAN,
S. AGGREGATION STATE OF MYCOBACTERIUM TUBERCULOSIS IMPACTS HOST IMMUNITY AND
AUGMENTS PULMONARY DISEASE PATHOLOGY. COMMUNICATIONS BIOLOGY.

FAULKNER, N., NG, K. W., WU, M. Y., HARVEY, R., MARGARITIS, M., PARASKEVOPOULOU,
S., HOULIHAN, C., HUSSAIN, S., GRECO, M., BOLLAND, W., WARCHAL, S., HEANEY, J.,
RICKMAN, H., SPYER, M., FRAMPTON, D., BYOTT, M., DE OLIVEIRA, T., SIGAL, A.,
KJAER, S., SWANTON, C., GANDHI, S., BEALE, R., GAMBLIN, S. J., MCCAULEY, J. W.,
DANIELS, R. S., HOWELL, M., BAUER, D., NASTOULI, E. & KASSIOTIS, G. REDUCED
ANTIBODY CROSS-REACTIVITY FOLLOWING INFECTION WITH B.1.1.7 THAN WITH PARENTAL
SARS-COV-2 STRAIN. ELIFE.

CROMARTY, R., SIGAL, A., LIEBENBERG, L. J., MCKINNON, L. R., ABDOOL KARIM, S.
S., PASSMORE, J. S. & ARCHARY, D. BETAMETHASONE INDUCES POTENT IMMUNOSUPPRESSION
AND REDUCES HIV INFECTION IN A PBMC IN VITRO MODEL. J INVESTIG. MED.


© 2022 . Bento theme by Satori Studio